These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 27771632)

  • 21. Anomalous observations on IPV and OPV vaccination.
    John TJ
    Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The polio endgame.
    Minor P
    Hum Vaccin Immunother; 2014; 10(7):2106-8. PubMed ID: 25608050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Remarks on the possibility of the introduction of fractionated dose of the inactivated poliomyelitis vaccine in the Latin American Child Immunization Schedule].
    Arbo A; Falleiros-Arlant LH; López EL; Brea Del Castillo J; Martínez de Cuellar C; Moreno G; Rolón R; Cerda J; Eguiazú S;
    Rev Chilena Infectol; 2018 Aug; 35(4):395-402. PubMed ID: 30534926
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Communications, Immunization, and Polio Vaccines: Lessons From a Global Perspective on Generating Political Will, Informing Decision-Making and Planning, and Engaging Local Support.
    Menning L; Garg G; Pokharel D; Thrush E; Farrell M; Kodio FK; Veira CL; Wanyoike S; Malik S; Patel M; Rosenbauer O
    J Infect Dis; 2017 Jul; 216(suppl_1):S24-S32. PubMed ID: 28838189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polio endgame: Lessons for the global rotavirus vaccination program.
    Jiang B; Patel M; Glass RI
    Vaccine; 2019 May; 37(23):3040-3049. PubMed ID: 31027927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC; Dutta A
    Vaccine; 2008 Sep; 26(39):4978-83. PubMed ID: 18680777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The challenge of changing the inactivated poliomyelitis vaccine in Latin America: declaration of the Latin American Society of Pediatric Infectious Diseases (SLIPE).
    Falleiros-Arlant LH; Avila-Agüero ML; Brea del Castillo J; Mariño C
    Rev Chilena Infectol; 2014 Oct; 31(5):590-603. PubMed ID: 25491459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polio Eradication and Endgame Plan - Victory within Grasp.
    Patel M; Menning L; Bhatnagar P
    Indian Pediatr; 2016 Aug; 53 Suppl 1():S28-S32. PubMed ID: 27771636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM; Sharma S; Tripathi B; Alvarez FP
    Public Health; 2017 Jan; 142():31-38. PubMed ID: 28057194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inactivated polio vaccine: time to introduce it in India's national immunization schedule.
    Verma R; Khanna P; Chawla S
    Hum Vaccin Immunother; 2012 Jul; 8(7):956-8. PubMed ID: 22699444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wild and vaccine-derived poliovirus circulation, and implications for polio eradication.
    Lopalco PL
    Epidemiol Infect; 2017 Feb; 145(3):413-419. PubMed ID: 27866483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE
    Dev Biol (Basel); 2001; 105():61-6. PubMed ID: 11763338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
    J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
    MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A vision of a world without polio: the OPV cessation strategy.
    Heymann DL; Sutter RW; Aylward RB
    Biologicals; 2006 Jun; 34(2):75-9. PubMed ID: 16682224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost analysis of post-polio certification immunization policies.
    Sangrujee N; Cáceres VM; Cochi SL
    Bull World Health Organ; 2004 Jan; 82(1):9-15. PubMed ID: 15106295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Polio Endgame: Lessons Learned From the Immunization Systems Management Group.
    Zipursky S; Vandelaer J; Brooks A; Dietz V; Kachra T; Farrell M; Ottosen A; Sever JL; Zaffran MJ
    J Infect Dis; 2017 Jul; 216(suppl_1):S9-S14. PubMed ID: 28838174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The moral dilemma of the polio eradication programme.
    John TJ; Dharmapalan D
    Indian J Med Ethics; 2019; 4 (NS)(4):294-297. PubMed ID: 31791935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Polio eradication: the OPV paradox.
    Dowdle WR; De Gourville E; Kew OM; Pallansch MA; Wood DJ
    Rev Med Virol; 2003; 13(5):277-91. PubMed ID: 12931339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.
    Pliaka V; Kyriakopoulou Z; Markoulatos P
    Expert Rev Vaccines; 2012 May; 11(5):609-28. PubMed ID: 22827246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.